Dr. Piyush Chandra

Doctors / Zydus Hospitals Vadodara

Consultant - Nuclear Medicine

MBBS, DNB, MD (Nuclear Medicine)


Industry Experience

7 years & counting


Educational Qualifications
  • MBBS
  • MD (Nuclear Medicine)
  • DNB (Nuclear Medicine, Gold Medalist)
  • FEBNM (Fellow, European Board of Nuclear Medicine)

Clinical Expertise

Expertise in all conventional nuclear medicine imaging procedures (renal, thyroid, bone scans) with special expertise in performing TMT/pharmacological stress myocardial perfusion SPECT for detection of coronary artery disease.

Voluminous experience in PET/CT and PET/MR imaging with special expertise in Cancer imaging with novel radiopharmaceuticals (Ga-68 PSMA, Ga-68 FAPI, F18-Choline and F18-DOPA)

Expertise in radionuclide therapies for various cancers with special expertise in treatment of liver, neuroendocrine and prostate malignancies (including use of Y90, Lu-177 and novel Ac-225 based ligands)


Areas of Medical Interest:

Molecular imaging of cancers, coronary artery disease, neurodegeneration / neuro-inflammation and novel radionuclide therapies for treatment refractory thyroid, prostate, neuroendocrine and liver malignancies.


Professional Bio

Dr. Piyush Chandra is presently associated with Zydus Hospitals Vadodara as Consultant - Nuclear Medicine. He has voluminous 7 years’ experience in advanced PET/CT and PET/MR imaging of cancers. He received his post graduate nuclear medicine training from Tata memorial center, Mumbai and additional radionuclide therapy training in Radiation medicine center, BARC, Mumbai and University hospital, Aachen, Germany.

He is certified in Radio-Pharmacy, Radiation Safety and High Dose Radionuclide Therapy practices. He has avid interests in clinical research with more than 40 pub-med indexed publications in peer reviewed national/international journals and has multiple awards for abstracts presentations at various conferences including the Best Young Author prize at annual European Association of Nuclear Medicine Congress, October 2021.